Bahraminia, Farhad, Azimi, Taher, Zangiabadian, Moein, Nasiri, Mohammad Javad, Goudarzi, Mehdi, Dadashi, Masoud, Imani Fooladi, Abbas Ali. (1400). Rifampicin-resistant tuberculosis in Iran: A systematic review and meta-analysis. , 24(6), 720-725. doi: 10.22038/ijbms.2021.47360.10901
Farhad Bahraminia; Taher Azimi; Moein Zangiabadian; Mohammad Javad Nasiri; Mehdi Goudarzi; Masoud Dadashi; Abbas Ali Imani Fooladi. "Rifampicin-resistant tuberculosis in Iran: A systematic review and meta-analysis". , 24, 6, 1400, 720-725. doi: 10.22038/ijbms.2021.47360.10901
Bahraminia, Farhad, Azimi, Taher, Zangiabadian, Moein, Nasiri, Mohammad Javad, Goudarzi, Mehdi, Dadashi, Masoud, Imani Fooladi, Abbas Ali. (1400). 'Rifampicin-resistant tuberculosis in Iran: A systematic review and meta-analysis', , 24(6), pp. 720-725. doi: 10.22038/ijbms.2021.47360.10901
Bahraminia, Farhad, Azimi, Taher, Zangiabadian, Moein, Nasiri, Mohammad Javad, Goudarzi, Mehdi, Dadashi, Masoud, Imani Fooladi, Abbas Ali. Rifampicin-resistant tuberculosis in Iran: A systematic review and meta-analysis. , 1400; 24(6): 720-725. doi: 10.22038/ijbms.2021.47360.10901

Rifampicin-resistant tuberculosis in Iran: A systematic review and meta-analysis

Iranian Journal of Basic Medical Sciences
مقاله 2، دوره 24، شماره 6، شهریور 2021، صفحه 720-725    اصل مقاله (773.75 K)
نوع مقاله: Review Article
شناسه دیجیتال (DOI): 10.22038/ijbms.2021.47360.10901
نویسندگان
Farhad Bahraminia1؛ Taher Azimi2؛ Moein Zangiabadian3؛ Mohammad Javad Nasiri4؛ Mehdi Goudarzi4؛ Masoud Dadashi5؛ Abbas Ali Imani Fooladi* 1
1Applied Microbiology research center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran
2Department of Pathobiology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
3Student Research Committee, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
5Department of Microbiology, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran
چکیده
Rifampicin (RIF)-resistant strain of Mycobacterium tuberculosis is an important barrier to effective tuberculosis (TB) treatment and prevention. The present study aimed to determine the frequency of RIF-resistant TB among patients with confirmed TB. Pubmed/Medline, Embase, Web of Science, and Scopus were searched for relevant articles published between January 1980 and January 2020. We pooled data with random-effects models when appropriate. After screening 1608 citations, 30 studies covering 8215 patients with TB were included. The pooled frequency of RIF-resistance among all patients with TB was 8.0% (95% CI 4.0–12.0). Our sub-group analysis showed that 4.0% of newly diagnosed cases and 36.0% of previously-treated TB patients from different settings in Iran were RIF-resistant. Our study showed that the frequency of RIF-resistance among patients with TB was 8.0%. Programmatic implementation of rapid drug susceptibility testing (DST) such as the Xpert MTB/RIF assay as a primary diagnostic test for persons suspected of having a RIF-resistant TB would be helpful for the control of the drug resistance. 
کلیدواژه‌ها
Drug resistance؛ Iran؛ Rifampicin؛ Tuberculosis؛ Xpert MTB/RIF assay
مراجع
آمار
تعداد مشاهده مقاله: 1,218
تعداد دریافت فایل اصل مقاله: 820
دانشگاه علوم پزشکی مشهد
آمار
تعداد نشریات29
تعداد شماره‌ها2,324
تعداد مقالات24,860
تعداد مشاهده مقاله82,752,245
تعداد دریافت فایل اصل مقاله45,816,810
اخبار نشریات